Skip to main content

Table 1 Characteristics of trials in the Gastrointestinal and Lymphoma Unit (n = 36)

From: Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey

Trial characteristic Number of trials (%)
(n = 36)
Study type  
 CTIMP 24 (67 %)
 Non-CTIMP 9 (25 %)
 Pre-screening 3 (8 %)
Sponsor  
 Royal Marsden 9 (25 %)
 Other academic institution 11 (31 %)
 Pharmaceutical company 16 (44 %)
Phase  
 I 2 (6 %)
 II 10 (28 %)
 II/III 2 (6 %)
 III 13 (36 %)
 Not applicable 9 (25 %)
Trial setting  
 Neoadjuvant 3 (8 %)
 Adjuvant 3 (8 %)
 Advanced 16 (44 %)
 Any 5 (14 %)
 Lymphomaa 9 (25 %)
Randomised trial  
 Yes 20 (56 %)
 No 16 (44 %)
Molecular screening  
 Yes 10 (28 %)
 No 26 (72 %)
Number of PIS (e.g. separate pharmacodynamics or imaging sub-studies)  
 1 20 (56 %)
 2 11 (31 %)
 3 4 (11 %)
 5 1 (3 %)
  1. Key: CTIMP = Clinical Trial of an Investigational Medicinal Product, pre-screening = molecular pre-screening to determine potential eligibility for a specific CTIMP study, PIS = patient information sheet
  2. aLymphoma trials were considered separately as the intent of lymphoma treatment is to induce remission and, therefore, the treatment paradigms differ from that of gastrointestinal malignancies